A randomized, controlled trial of interferon alfa-2b
alone and after prednisone withdrawal for the treatment of chronic hepatitis B.
Although interferon alfa-2b
is approved for the intralesional treatment of genital warts and subcutaneously for Kaposi's sarcoma and malignant melanoma, among other conditions, it's off-label therapy for BCCs.
Durability of sustained virological response in patients with chronic hepatitis C after treatment with interferon Alfa-2b
alone or in combination with ribavirin.
Major Finding: In cirrhotic and noncirrhotic patients treated with boceprevir, pegylated interferon alfa-2b
, and ribavirin, 57% of patients with cirrhosis and anemia treated with a ribavirin dose reduction had a sustained virologic response, compared with 64% of those treated with erythropoietin.
Pegylated interferon alfa-2b
or pegylated interferon alfa-2a in combination with ribavirin is the standard treatment for HCV infection, achieving response rates of 40% to 60% for patients with HCV genotype 1, (32) and higher rates for those with HCV genotypes 2 and 3.
Randomised trial of interferon alfa-2b
plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b
plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Recombinant human albumin-interferon alfa (alb-IFN) is an 85 kilodalton recombinant fusion protein consisting of human serum albumin genetically fused to interferon alfa-2b
Chodosh says these results suggest that "topical interferon alfa-2b
and aggressive surgical excision can both be considered effective treatments for OSSN.
Long-term follow-up of non-HIV kaposi sarcoma treated with low-dose recombinant interferon alfa-2b
has similar actions to natural interferon.
Among the goals of this clinical trial is to find the highest tolerable dose of VQD-001 combined with Interferon alfa-2b
in the treatment of patients with advanced cancer that have not responded to standard treatment or where there is no standard treatment for that type of cancer.
HCV-796 interferes with the replication of hepatitis C virus (HCV), and the objectives of the trial are to assess its safety, tolerability, pharmacokinetic profile and antiviral activity when used in combination with pegylated interferon alfa-2b
plus ribavirin, compared to the current standard of care in treatment-naive subjects with HCV genotype 1 infection and in patients with HCV genotype 1 infection who were non-responders to prior HCV therapy.
Twelve weeks of interferon alfa-2b
plus ribavirin is just as effective as 24 weeks of the treatment in maintaining a sustained response in patients with genotype 2 or 3 chronic hepatitis C infection who respond to treatment at 4 weeks, according to the results of an open-label, randomized trial.
There are several FDA-approved therapies for chronic hepatitis C: interferon alfa-2b
, interferon alfa-2a, interferon alfacon-1, peginterferon alfa-2b, peginterferon alfa-2a, and each, except for interferon alfacon-1, in combination with ribavirin.
The Schering Plough Brinny site, in operation for more than 25 years, manufactures Interferon alfa-2b
used in the treatment of malignant melanoma, chronic hepatitis B & C, and other illnesses.